Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07796568

Virtual Group Therapy for IBD Patients With Anxiety and Depression

This study is being done to better understand the complex relationship between mental health and Inflammatory Bowel Disease (IBD), with a particular focus on symptoms of depression and anxiety. While depression and anxiety have traditionally been viewed as reactions to the burden of living with IBD, new research suggests that the biological factors involved in IBD may also contribute directly to these mental health challenges. This study aims to evaluate whether a virtual, group-based psychological treatment is both acceptable and feasible for patients with IBD who experience significant depression and/or anxiety. Researchers will also evaluate participants' depression, generalized anxiety, and associated psychosocial factors (poor sleep quality, GI-specific anxiety, fatigue) before, during, and after treatment. Finally, researchers will evaluate disease severity as it relates to mental health status by comparing it to symptoms, biochemical disease and tryptophan metabolites from blood and stool samples.

People who agree to join the study will be asked to attend three in-person visits and 10 virtual group psychotherapy sessions over 11 weeks. Participants will be asked to complete questionnaires, give stool and blood samples, and the research team will collect information about participations from medical records.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Chicago

Chicago, Illinois, 60637, United States

Location contact

Alyse Bedell, PhD, CST

PRINCIPAL_INVESTIGATOR

Lead Study Coordinator

CONTACT

[email protected]

872-303-7886

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18+ years of age
  • Patients with Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)
  • English-speaking
  • Patients with score ≥10 on General Anxiety Disorder-7 (GAD-7) questionnaire (considered moderate or higher anxiety symptoms) or ≥10 on the Patient Health Questionnaire-9 (PHQ-9) (considered moderate or higher depressive symptoms) within 3 months
  • Able to provide written consent

Exclusion criteria

  • Unwilling and/or unable to participate
  • Non-English speakers
  • Unable to understand the instructions or to consent to participation in the study, including patients with a diagnosed cognitive impairment

Treatment and study plan

Group Psychotherapy Intervention

Behavioral

Participants will engage in a course of ten, 120-minute sessions of group psychotherapy. The intervention will be guided by the Mind Over Mood treatment manual. Mind Over Mood is a manual that is published and commonly used to treat depression and anxiety as guided by a therapist and for self-help. For this study, the manual will be adapted for patients with IBD. Session content will include interventions such as psychoeducation on the brain-gut connection and the CBT model, behavioral activation and activity scheduling, cognitive monitoring and restructuring, development of behavioral experiments to test underlying assumptions, building acceptance and gratitude, and maintenance of gains and relapse prevention.

Primary outcomes

  1. Determine acceptability of a 10-session, group-based, virtual treatment guided by the Mind over Mood treatment manual in patients with IBD with clinically significant depression and/or anxiety

    Time frame: End of intervention at week 10

    Acceptability will be assessed using the Client Satisfaction Questionnaire-4 (CSQ-4), which is used to measure overall satisfaction and client self-efficacy in healthcare, mental health, and social programs. Scores range from 4-16, with higher scores indicating higher satisfaction with the treatment. CSQ-4 scores are commonly classified as "low satisfaction/dissatisfaction" (4-8), "moderate/neutral satisfaction" (9-12), and "high satisfaction" (13-16).

  2. Determine feasibility of a 10-session, group-based, virtual treatment guided by the Mind over Mood treatment manual in patients with IBD with clinically significant depression and/or anxiety

    Time frame: End of treatment at 10 weeks

    Feasibility will be assessed by analyzing recruitment and retention (i.e., number of patients who are referred that enroll in the study and complete treatment)

Secondary outcomes

  1. Change in depression

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Measured via Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report tool used to screen, diagnose, and measure the severity of depression in clinical settings. It scores depressive symptoms experienced over the past two weeks on a scale from 0 to 27, with higher scores indicating more severe symptoms. Scores are commonly classified as "minimal or no depression" (0-4), "mild depression" (5-9), "moderate depression" (10-14), "moderately severe depression" (15-19), and "severe depression" (20-27).

  2. Change in anxiety

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Measured via Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report tool used to screen for anxiety and measure its severity over the past two weeks. Scores range from 0-21, with higher numbers indicating more severe symptoms. GAD-7 scores are commonly classified as "minimal anxiety" (0-4), "mild anxiety" (5-9), "moderate anxiety" (10-14), and "severe anxiety" (15-21).

  3. Change in fatigue

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Measured via Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), 13-item tool that measures tiredness and how it affects daily life over the past 7 days. Scores range from 0-52, with higher numbers indicating less fatigue. FACIT-Fatigue scores are commonly classified as "severe fatigue" (0-21), "moderate fatigue" (22-30), "mild fatigue" (31-40), and "little to no fatigue" (40-52).

  4. Change in sleep quality

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Measured via Pittsburgh Sleep Quality Index (PSQI), 19-item self-report questionnaire that evaluates subjective sleep quality and disturbances over a one-month time period. Scores range from 0-21, with higher numbers indicating worse sleep quality. PSQI scores are commonly classified as "good sleep quality" (0-5) and "poor sleep quality" (6-21).

  5. Change in gastrointestinal symptom-specific anxiety (GSA)

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Measured via Visceral Sensitivity Index (VSI), a 15-item self-report questionnaire that evaluates GSA, including fear, hypervigilance, and avoidance of belly sensations. Scores range from 0-75, with higher numbers indicating worse GSA.

  6. Change in clinical IBD outcomes (CD)

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Measured for patients with CD via change in scores on the Harvey Bradshaw Index (HBI), a clinical tool used to measure the severity of CD based on five patient symptoms from the previous day. Scores range from 0-16 and up, with higher numbers indicating more severe disease activity. HBI scores are commonly classified as "clinical remission" (0-4), "mild disease activity" (5-7), "moderate disease activity" (8-16), and "severe disease activity" (16 or more).

  7. Change in clinical IBD outcomes (UC)

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Measured for patients with UC via change in scores on the Simple Clinical Colitis Activity Index (SCCAI), a clinical tool used to measure the severity of UC. Scores range from 0-5 and up, with higher numbers indicating more severe disease activity. UC scores are commonly classified as "clinical remission" (0-2), "mild disease activity" (3-4), and "active flare or relapse" (5 or more).

  8. Change in biomedical IBD outcomes

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Change in biochemical inflammation measured by fecal calprotectin and c-reactive protein levels.

  9. Change in targeted metabolites including compounds from tryptophan metabolism

    Time frame: Before, during, and after treatment (weeks 0, 5, and 10).

    Change in untargeted metabolite levels

Study contacts

Contact information is provided by the study sponsor or research team.

Lead Study Coordinator

CONTACT

[email protected]

872-303-7886

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Collaborators

  • GI Research Foundation

Registry information

Official study title

Group-based Virtual Psychotherapy Intervention for Anxiety and Depression in Patients With Inflammatory Bowel Disease

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 1, 2026
Registry last updated
Sep 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.